ARTIVA BIOTHERAPEUTICS, INC. COMMON STOCK
NASDAQ: ARTV (Artiva Biotherapeutics, Inc.)
Kemas kini terakhir: 16 minit lalu4.18
-0.02 (-0.36%)
| Penutupan Terdahulu | 4.19 |
| Jumlah Dagangan | 576,845 |
| Harga / Buku (P/B) | 0.590 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -6.04 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -100.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.29% |
| Nisbah Semasa (MRQ) | 13.93 |
| Aliran Tunai Operasi (OCF TTM) | -59.79 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -36.41 M |
| Pulangan Atas Aset (ROA TTM) | -33.29% |
| Pulangan Atas Ekuiti (ROE TTM) | -68.14% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Artiva Biotherapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.7 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 0.0 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.84 |
|
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 19.99% |
| % Dimiliki oleh Institusi | 89.73% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ra Capital Management, L.P. | 30 Jun 2026 | 17,955,642 |
| Viking Global Investors Lp | 30 Jun 2026 | 2,604,166 |
| Blackstone Inc. | 30 Jun 2026 | 2,403,437 |
| 5Am Venture Management, Llc | 30 Jun 2026 | 2,353,304 |
| Venrock Adviser, Llc | 30 Jun 2026 | 2,043,596 |
| Caligan Partners Lp | 30 Jun 2026 | 1,736,111 |
| Samsara Biocapital, Llc | 30 Jun 2026 | 954,861 |
| Blue Owl Capital Holdings Lp | 30 Jun 2026 | 874,542 |
| Propel Bio Management, Llc | 30 Jun 2026 | 696,436 |
| Silverarc Capital Management, Llc | 30 Jun 2026 | 525,000 |
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |